

Metabolic snapshot of plasma samples reveals new pathways implicated in SARS-CoV-2 pathogenesis

Oihane E. Albyniga^{1¶}, Daniel Jiménez^{2¶}, Matilde Sánchez-Conde², Pilar Vizcarra², Raquel Ron², Sabina Herrera², Javier Martínez-Sanz², Elena Moreno², Santiago Moreno², Coral Barbas^{1§*}, Sergio Serrano-Villar^{2§*}

¹ Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain.

² Servicio de Enfermedades Infecciosas, Hospital Universitario Ramón y Cajal, IRYCIS, Carretera de Colmenar Viejo km 9.100, 28034 Madrid, Spain.

[¶]Co-authors

[§]Co-senior authors

*Corresponding authors: Sergio Serrano-Villar. Department of Infectious Diseases. Hospital Universitario Ramón y Cajal. Ctra. de Colmenar Viejo, km 9.100, 28034 Madrid, Spain. Email: sergio.serrano@salud.madrid.org. Coral Barbas. Centro de Metabolómica y Bioanálisis (CEMBIO), Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, Boadilla del Monte, 28660 Madrid, Spain. E-mail: cbarbas@ceu.es.

Abstract

Despite of the scientific and human efforts to understand COVID-19, there are questions still unanswered. Variations in the metabolic reaction to SARS-CoV-2 infection could explain the striking differences in the susceptibility to infection and the risk of severe disease. Here, we used untargeted metabolomics to examine novel metabolic pathways related to SARS-CoV-2 susceptibility and COVID-19 clinical severity using capillary electrophoresis coupled to a time-of-flight mass spectrometer (CE-TOF-MS) in plasma samples. We included 27 patients with confirmed COVID-19 early after symptom onset who were prospectively followed and 29 healthcare workers heavily exposed to SARS-CoV-2 but with low susceptibility to infection ('nonsusceptible'). We found that the metabolite profile was predictive of the study group. We identified a total of 55 metabolites as biomarkers of SARS-CoV-2 susceptibility or COVID-19 clinical severity. We report the discovery of new plasma biomarkers for COVID-19 that provide mechanistic explanations for the clinical consequences of SARS-CoV-2, including mitochondrial and liver dysfunction as a consequence of hypoxemia (citrulline, citrate, and BAIBA), energy production and

amino acid catabolism (L-glycine, L-alanine, L-serine, L-proline, L-aspartic acid and L-histidine), endothelial dysfunction and thrombosis (citrulline, L-ADMA, 2-AB, and Neu5Ac), and we found interconnections between these pathways. In summary, in this first report of the metabolomic profile of individuals with severe COVID-19 and SARS-CoV-2 susceptibility by CE-MS, we define several metabolic pathways implicated in SARS-CoV-2 susceptibility and COVID-19 clinical progression that could be developed as biomarkers of COVID-19.

Keywords: SARS-CoV-2; COVID-19; biomarkers; metabolomics; disease susceptibility; clinical progression; metabolites; oxidative stress response.

Introduction

Despite the effective response to the worst pandemic that humanity has faced in recent decades, the metabolic and biochemical processes during SARS-CoV-2 infection remain poorly understood. Most studies that have thus far investigated the biochemical pathways affected by SARS-CoV-2 rely on powerful bioanalytical techniques. Using untargeted and targeted metabolomics, other groups have identified that disruption of lipid and amino acid metabolism, such as the kynurenine pathway, are potentially relevant pathways associated with COVID-19 pathogenesis (1–5). Other candidate pathways that could be involved in clinical progression include pyrimidine (1,2) and purine (1,6–8) metabolism, fructose, and mannose metabolism (1,7) and carbon metabolism (1,2,9), although the specific mechanism remains unclear. Overall, the necessity to elucidate the global snapshot of biochemical processes behind SARS-CoV-2 infection is still in progress.

Metabolomic profiling can be performed by mass spectrometry (MS) coupled to a separation technique such as liquid chromatography (LC-MS), gas chromatography (GC-MS) or capillary electrophoresis (CE-MS). CE-MS is used to study polar and ionizable compounds such as free modified amino acids (MAAs) and “epimetabolites”, which are side products of enzyme reactions. These MAAs or the appearance of epimetabolites has been associated with important alterations in cellular, physiological, and pathological processes(10–13). While CE-MS is a powerful method to characterize unknown mechanisms of disease progression, to our knowledge, it has not been used in individuals with COVID-19.

Here, we investigated novel metabolic pathways of SARS-CoV-2 susceptibility and COVID-19 clinical progression using CE-MS in longitudinal plasma samples from patients with COVID-19 with different disease severities and in a population of

healthcare workers heavily exposed to SARS-CoV-2 but with low susceptibility to infection.

Results

General characteristics of the study population

We included 63 adults, of whom 27 were in the COVID-19+ group and 36 were in the COVID-19- group, of whom 24 were nonsusceptible. COVID-19+ and susceptible patients were older and had a higher prevalence of comorbidities than COVID-19- and nonsusceptible patients. The general characteristics of the study population are described in **Table 1**.

Table 1. General characteristics of the study population

	COVID19- (N=36)	COVID19+ (N=27)	Mild disease (N=11)	Moderate disease (N=11)	Severe disease (N=5)	Non- susceptible (N=28)	Susceptible (N=31)	<i>p</i>-value COVID19+ vs. COVID19-	<i>p</i>-value (susceptible vs. nonsusceptible)
Age, median (P25-P75)	42 (36-51)	71 (55-85)	57 (50-75)	85 (75-89)	71 (59-92)	43 (36-51)	66 (50-85)	<0.001	<0.001
Sex, % women	26 (72)	14 (52)	5 (45)	6 (55)	3 (60)	22 (79)	17 (55)	0.097	0.054
Obese, N (%)	2 (6)	7 (26)	3 (27)	2 (18)	2 (40)	2 (7)	7 (23)	0.022	0.100
Hypertension, N (%)	2 (6)	14 (52)	6 (55)	5 (45)	3 (60)	1 (4)	14 (45)	<0.001	<0.001
Previous lung disease, N (%)	2 (6)	3 (11)	1 (9)	2 (18)	0 (0)	2 (7)	3 (10)	0.841	0.698
Previous heart disease, N (%)	1 (3)	6 (22)	2 (18)	2 (18)	2 (40)	0 (0)	6 (20)	0.017	0.012
Days from onset of symptoms to hospitalization, median (P25-P75)	-	4 (2-7)	7 (4-10)	3 (2-7)	5 (3-6)	-	-	-	-

Differences in metabolic profiles according to COVID-19 disease status and SARS-CoV-2 susceptibility

Using an untargeted metabolomics approach and after data matrix filtration, 166 features (pairs of m/z –RT) were obtained in plasma samples with proper reproducibility. We first evaluated the differences between the metabolomes of COVID-19+ and COVID-19- participants, as well as between susceptible and nonsusceptible individuals, by building principal component analysis (PCA) and partial least squares-discriminant analysis (PLS-DA) score plots. As shown in **Fig S1 AB** and **Fig S2 AB**, the metabolomes of COVID-19+ vs. COVID-19-, as well as susceptible vs. nonsusceptible participants, drastically differed, indicating that the metabolomic fingerprints predicted the study group. Then, we performed orthogonal partial least squares-discriminant analysis (OPLS-DA) and found that the separation was totally explained through PC1 (**Fig 1**). The p -values for the OPLS-DA models were 2.10×10^{-19} and 4.20×10^{-17} for COVID-19 disease and COVID-19 susceptibility, respectively, corroborating previous observations. Using predefined statistical criteria for variable selection ($VIP \geq 1$ and $|p(\text{corr})| \geq 0.5$), we defined 10 metabolites predicting COVID-19 status and 11 predicting SARS-CoV-2 susceptibility (**Table S1**).




Fig 1. Untargeted metabolomic profiles of COVID19+ vs COVID19- and susceptible vs. non-susceptible participants using supervised OPLS-DA models for CE-MS data. (A) Plot

A represents the comparison of COVID-19+ and COVID-19- individuals ($R^2 = 0.878$, $Q^2 = 0.813$), and CV-ANOVA (p -value = 2.10×10^{-19}). (B) Plot B represents the comparison of susceptible and non-susceptible participants with $R^2 = 0.902$, $Q^2 = 0.817$, and CV-ANOVA p -value = 4.20×10^{-17} . Models were validated by permutation testing and CV-ANOVA(14,15). Hydroxychloroquine, initially found to be significant, was removed from all statistical analysis as it was empirically used to treat COVID-19 at the time of sample collection.

Metabolic profile differences associated with COVID-19 clinical severity

We then performed subgroup analyses separating COVID-19+ participants by clinical severity. While no differences in untargeted metabolomic profiles were found in the PCA (**Fig S1 C**), inspection of the PLS-DA score plots (**Fig S2 C**) showed clear clustering that did not meet the prespecified validation criteria. Pairwise comparisons of OPLS-DA models of all 3 categories fulfilled the validation criteria, indicating that there were statistically significant differences in the metabolomes of mild vs. severe and between moderate vs. severe cases (**Fig 2**). Similar to other COVID-19 and susceptibility studies, a total of 8 metabolites, including creatine, citrulline and 6 unknown features, were identified as predictors of greater disease severity ($VIP \geq 1$ and $|p(\text{corr})| \geq 0.5$) (**Table S1**).




Fig 2. Untargeted metabolomic profiles of participants with COVID19 according to clinical severity using supervised OPLS-DA models for CE-MS data. (A) Mild vs. moderate disease; $R^2 = 0.713$, $Q^2 = 0.009$, and CV-ANOVA p -value = 0.997. (B) Mild vs. severe disease; $R^2 = 0.929$, $Q^2 = 0.675$, and CV-ANOVA p -value = 0.010. (C) Moderate vs. severe disease; $R^2 = 0.897$, $Q^2 = 0.636$, and CV-ANOVA p -value = 0.027.

Longitudinal changes in the metabolomes of participants with COVID-19

We then sought to assess the effect of time on the metabolomes of participants with COVID-19 following a similar strategy. A clear separation between baseline and day 8 was found for mild and moderate cases (Fig S1 D1-D3; Fig S2 D1-D2). For severe cases, the PLS-DA model could not be fitted due to the limited availability of paired samples.

Validated OPLS-DA models (Fig 3) showed that the longitudinal differences detected for mild and moderate cases were statistically significant (CV-ANOVA p -value < 0.05 and $R^2 - Q^2 < 0.3$). We found 10 metabolites whose abundance differed from baseline to day 8 in mild cases and 7 in moderate cases ($VIP \geq 1$ and $|p(\text{corr})| \geq 0.5$), see S1 Table).




Fig 3. Untargeted metabolomic profiles at baseline and day 8 of participants with mild and moderate COVID19 supervised OPLS-DA models for CE-MS data. (A) Plot A represents the differences in mild cases ($R^2 = 0.816$, $Q^2 = 0.596$; CV-ANOVA p -value = 0.062). (B) Plot B represents the differences in moderate cases ($R^2 = 0.961$, $Q^2 = 0.716$; CV-ANOVA p -value = 0.014).

Complementary characterization of metabolomic predictors of COVID-19 disease status and susceptibility

To visually summarize the metabolite fingerprint associated with COVID-19 disease and SARS-CoV-2 susceptibility, we represented the abundance of the metabolites identified by univariate analysis followed by multivariate statistical analysis as predictors of each condition in heatmaps with hierarchical clustering (Fig 4, Fig S3 and Fig S4). As shown in the heatmap (Fig 4), COVID-19+ (mild, moderate, and severe

patients) had more similarities than COVID-19- individuals. The heatmap shows clear patterns of the distinct metabolic biomarkers for each group.




Fig 4. Heatmap with group average of statistically significant metabolites detected in human plasma samples by CE-MS modified by virus SARS-CoV-2 virus infection. In green, metabolites involved in TCA cycle. In purple, those involved in kynurenine pathway. In blue those compounds of the nitric oxide or are related with NO regulation.

ANOVA-simultaneous component analysis (ASCA) identified age as the only factor significantly associated with the outcome. Thus, we further assessed the metabolites previously identified as predictors of COVID-19 disease severity or susceptibility controlling for age using ANCOVA (Tables S2 and S3). Of them, NG, NG'-dimethyl-L-arginine (L-SDMA), L-cystine and L-carnitine lost statistical significance. L-Kynurenine and citric acid remained significantly predictive of COVID-19 disease and SARS-CoV-2 susceptibility, respectively. The selection of metabolites that could be fully characterized and their size effects are summarized in **Table 2**.

168 **Table 2. Fold change of metabolite abundance in plasma samples associated with COVID19 disease status and susceptibility.**

Compound	COVID19+ vs. COVID19-	Susceptible vs. Nonsusceptible	Severe vs. Mild	COVID19+ day 8 vs baseline
L-Glycine	nssd	↓ 0.86	nssd	nssd
L-Alanine	↓ 0.85	↓ 0.85	nssd	nssd
N,N-Dimethylglycine	nssd	nssd	nssd	↑ 1.21
2-Aminobutyric acid	↑ 1.37	nssd	nssd	nssd
3-Aminoisobutyric acid	↑ 1.66	nssd	nssd	nssd
L-Serine	↓ 0.86	↓ 0.85	nssd	nssd
L-Proline	↓ 0.83	↓ 0.84	nssd	nssd
Creatine	nssd	nssd	↑ 2.47	nssd
L-Aspartic acid	nssd	↓ 0.87	nssd	nssd
L-Histidine	↓ 0.81	↓ 0.80	nssd	nssd
N2-Methyl-L-Lysine	nssd	nssd	nssd	↑ 1.5
L-Phenylalanine	↑ 1.16	nssd	nssd	nssd
Citrulline	↓ 0.81	↓ 0.80	↓ 0.56	nssd
Citric acid	↓ 0.80	nssd	nssd	nssd
NG,NG-Dimethyl-L-Arginine	↑ 1.17	nssd	nssd	nssd
L-Tryptophan	↓ 0.68	↓ 0.67	nssd	nssd
L-Kynurenine	↑ 1.53	nssd	nssd	nssd
N-Acetylneuraminic acid	↑ 1.81	↑ 1.8	nssd	nssd

169 Blue color denotes the fold change representing the increase of metabolite abundance and red color represents the decreases (see Table

170 S1 for additional information).

Discussion

To our knowledge, this study is the first to evaluate the plasma metabolomic profile of individuals with severe COVID-19 and SARS-CoV-2 susceptibility by CE-MS. Our work demonstrates the potential of CE-MS to unveil new plasma biomarkers of COVID-19 and SARS-CoV-2 susceptibility and allows a deeper advancing of the metabolic consequences of SARS-CoV-2 infection (Fig 5).




Fig 5. A model of the metabolic pathways implicated in COVID19 pathogenesis. Impairment of blood oxygenation following SARS-CoV-2 damage results in 1) inefficient mitochondrial

181 metabolism in the liver, resulting in dysregulation of the urea cycle citrulline decreases,
182 phenylalanine increases; 2) dysregulation of energy metabolism and amino acid
183 metabolism, resulting in decreased L-serine, L-alanine, and L-serine; 3) activation of
184 oxidative stress response, resulting in BAIBA accumulation, L-ADMA upregulation, and
185 induction of the kynurenine pathway, which impairs mucosal immunity, allowing bacterial
186 superinfections. Figure generated using biorender.com.

187 Among the significant metabolites, we found that the citrulline concentration decreases
188 over the course of COVID-19 disease, but low levels early on in the course of the disease
189 are associated with greater clinical severity. This finding is consistent with those reported
190 in a recent work, where carbamoyl phosphate levels, a substrate for citrulline biosynthesis
191 in the mitochondria of liver cells, decreased with greater disease severity (1). Because
192 citrulline is an intermediate in the urea cycle and a byproduct of the enzymatic production
193 of nitric oxide from arginine (16), these findings point to either dysregulation in the urea
194 cycle or liver dysfunction as the underlying mechanism explaining the links between this
195 metabolite and COVID-19. Furthermore, increased levels of circulating phenylalanine,
196 which were found to be associated with COVID-19 in our study, have also been reported
197 in patients with hepatic fibrosis, acute hepatic failure and hepatic encephalopathy as well
198 as in COVID-19 disease (5).

199 Apart from phenylalanine, other amino acids (AAs) were found to be significantly different
200 between the groups (Table 2). Among them, L-glycine, L-alanine, L-serine, L-proline, L-
201 aspartic acid and L-histidine were downregulated in patients. Previous studies have
202 revealed that SARS-CoV-2 infection dysregulates pathways linked to energy production and
203 amino acid catabolism (17,18). In a murine model of SARS-CoV-2, Li *et al.* found several
204 genes commonly downregulated in multiple organs that led to significant enrichment in
205 pathways related to oxidative phosphorylation and the electron transport chain (17). As the
206 tricarboxylic acid (TCA) cycle is connected to the electron transport chain, they also

207 analyzed genes associated with the TCA cycle. They found that several TCA cycle genes
 208 were downregulated and that TCA cycle metabolites were decreased in animal serum (17).

209 Apart from the AAs that lead to intermediates of the TCA cycle that were downregulated in
 210 the COVID-19+ group, the significant downregulation of citrate also suggested that SARS-
 211 CoV-2 results in inefficient mitochondrial metabolism (18,19), which can be interpreted as
 212 the metabolic response to impaired oxygenation secondary to lung damage (9). Citrate is a
 213 direct TCA cycle metabolite obtained by the action of citrate synthase from oxaloacetate.
 214 The gene encoding this enzyme exhibits decreased expression (17). Different genes,
 215 proteins and/or metabolites involved in the TCA cycle have been found to be suppressed
 216 or downregulated in individuals with COVID-19 (18,19).

217 An intriguing finding in our study is the upregulation of 3-aminoisobutyric acid (BAIBA)
 218 associated with COVID-19. BAIBA is a catabolite of thymine and valine metabolism that has
 219 been proposed as a novel regulator of carbohydrate and lipid metabolism associated with
 220 aerobic exercise (20). Although little is known about the implications of BAIBA in
 221 pathogenesis, the fact that two enantiomers of BAIBA (R-BAIBA and S-BAIBA) are ultimately
 222 metabolized in mitochondria further supports the idea that mitochondrial and TCA cycle
 223 abnormalities are a metabolic hallmark of COVID-19 pathogenesis, as also indicated by the
 224 abnormalities detected in amino acid and citrate metabolism (21). As BAIBA is primarily
 225 metabolized by mitochondria, the accumulation of BAIBA in patients with COVID-19 could
 226 be explained by a reduction in mitochondrial functionality and TCA cycle suppression
 227 following impairment of blood oxygenation. To our knowledge, BAIBA has never been
 228 proposed as a putative metabolite involved in COVID-19 disease. This result is of special
 229 interest not only to further investigate BAIBA as a novel biomarker for COVID-19 disease
 230 but also to elucidate its role in metabolism under physiological stress conditions or
 231 hypoxemia.

232 We also found evidence that SARS-CoV-2 affects metabolic pathways implicated in
 233 endothelial dysfunction, thrombosis, and cardiovascular disease. First, nitric oxide synthase
 234 (NOS) is an enzyme that catalyzes the production of citrulline and nitric oxide (NO) from
 235 arginine. This enzyme is inhibited by asymmetric dimethylarginine (L-ADMA), which is
 236 upregulated in COVID-19 patients and is an endogenous competitor of arginine, the nitric
 237 oxide precursor (22). L-ADMA has been associated with elevated oxidative stress (23). The
 238 higher L-ADMA concentrations found in individuals with COVID-19 suggest inhibition of
 239 NOS activity, which would ultimately result in decreased levels of NO. Because NO is
 240 among the principal redox molecules exploited by the immune system as a defensive
 241 mechanism, NO has been implicated in the control of viral replication, including that of
 242 HIV, influenza A and B, and vaccinia virus (24,25). Because it is as-yet unexplained how
 243 SARS-CoV-2 produces severe endothelial injury, widespread thrombosis and
 244 microangiopathy (26), our findings offer a new mechanistic explanation for this hallmark of
 245 SARS-CoV-2 pathogenesis and point to the nitric oxide synthesis pathway as a potential
 246 therapeutic target. Second, 2-aminobutyric acid (2-AB) and N-acetylneuraminic acid
 247 (Neu5Ac) were also upregulated in the COVID-19+ group. 2-AB is a marker that seems to
 248 be a compensatory mechanism to oxidative stress (27) and has been implicated in the
 249 modulation of glutathione metabolism in the myocardium (28). This finding indicates that
 250 2-AB deserves further attention as a biomarker of the myocardial dysfunction associated
 251 with COVID-19 (29). Finally, Neu5Ac is the most widespread form of sialic acids and is a
 252 family of compounds with a broad range of implications in human physiology (30). Because
 253 Neu5Ac concentrations have been correlated with the development of cardiovascular
 254 disease via RhoA signaling pathway activation (31,32), the fact that we found higher Neu5Ac
 255 concentrations associated with COVID-19 provides a new pathway possibly linked to the
 256 excess risk of cardiovascular diseases associated with SARS-CoV-2.

257 Inflammation gained early attention as a crucial mechanism of SARS-CoV-2 pathogenesis
 258 (33). Indoleamine-2,3-dioxygenase-1 (IDO1), which is involved in tryptophan catabolism via

the kynurenine pathway, is correlated with epithelial barrier disruption, bacterial translocation and inflammation in other viral infections (34). Induction of IDO1 results in the production of kynurenine derivatives with immunosuppressive effects, impairing mucosal immunity and promoting bacterial translocation and higher mortality (35). Impairment of the kynurenine pathway, resulting in reduced tryptophan (Trp) and elevated kynurenine (Kyn) levels associated with COVID-19, has previously been reported (3,7,36). Our data reveal not only the same tendency for Trp and Kyn but also the increasing tendency of the Kyn/Trp ratio with severity. This ratio has previously been associated with renal insufficiency in patients with SARS-CoV-2 and in many other diseases, such as inflammatory lung disease (5,37). Strikingly, IDO activity is induced by interferon-gamma (IFN- γ), as well as other cytokines and mediators (38,39), and it is inhibited in oxidative stress conditions by NO (39,40). Considering the reduction in NO synthesis mentioned previously, the alterations observed in the kynurenine pathway could be a result of the aforementioned metabolic abnormalities and result in further impairment of mucosal immunity, providing an explanation for the significant rates of bacterial pneumonia associated with COVID-19 (35).

The major strengths of our study include 1) the inclusion of COVID-19 cases in an early phase since the onset of symptoms, 2) the assessment of a special population of nonsusceptible individuals, 3) the high-throughput CE-MS method used to characterize the metabolome of the study participants, and 4) the inclusion of follow-up samples to assess the longitudinal variations of the plasma metabolites in a subset of participants. Our study is also subject to some limitations. First, the samples were collected during the first COVID-19 wave in Madrid. It is unknown yet whether the emerging SARS-CoV-2 variants could lead to different metabolic consequences. Second, as expected, cases in the severe group were older and had more comorbidities than milder cases, so we considered potential confounders in our statistical approach. Third, in the subgroup analyses separated by

285 clinical severity, the statistical power to detect differences in metabolite abundances was
286 lower due to the smaller sample sizes.

287 In summary, in this work examining for the first time the metabolic changes associated with
288 COVID-19 by CE-MS, we report the discovery of new plasma biomarkers for COVID-19 that
289 provide mechanistic explanations for the clinical consequences of SARS-CoV-2, including
290 mitochondrial and liver dysfunction as a consequence of hypoxemia (citrulline, citrate and
291 BAIBA), energy production and amino acid catabolism (L-glycine, L-alanine, L-serine, L-
292 proline, L-aspartic acid and L-histidine), and endothelial dysfunction and thrombosis
293 (citrulline, L-ADMA, 2-AB, and Neu5Ac), and we found interconnections between these
294 pathways (**Figure 5**). These biomarkers deserve further attention as biomarkers of SARS-
295 CoV-2 susceptibility and COVID-19 clinical severity and as potential targets for
296 interventions.

297 **Material and methods**

298 **Reagents**

299 All reagents, solvents and standards used for sample treatment and subsequent analysis are
300 described in the Supporting Information.

301 **Patient enrollment and sample collection**

302 We analyzed data from adults recruited at Hospital Universitario Ramón y Cajal, Madrid,
303 Spain. Participants had confirmed SARS-CoV-2 (COVID-19+ group) infection by PCR from
304 nasopharyngeal swabs, sputum, or lower respiratory tract secretions within the first 7 days
305 from the onset of symptoms and were classified according to clinical severity as follows:
306 mild disease, defined as those without a need for supplemental oxygen and who were
307 asymptomatic one week after diagnosis; moderate disease, defined as the presence of

308 bilateral radiologic infiltrates or opacities and clinical assessment requiring supplemental
 309 oxygen; and severe disease, defined as the development of acute respiratory distress
 310 syndrome (41). Hospitalized participants provided samples at baseline and 8 days later.
 311 Participants without SARS-CoV-2 (COVID-19- group) were asymptomatic subjects with a
 312 negative PCR from nasopharyngeal swabs. We considered adults to be “susceptible” when
 313 they had positive IgG for SARS-CoV-2 or previous COVID-19 confirmed by polymerase
 314 chain reaction (PCR) from nasopharyngeal exudate. Nonsusceptible adults were healthy
 315 healthcare workers who had been on duty for at least three months in COVID-19 wards or
 316 intensive care units and reported at least three high-risk exposures to SARS-CoV-2 (42)
 317 without having experienced symptoms suggestive of SARS-CoV-2 infection, were
 318 persistently negative for SARS-CoV-2 PCR testing and did not have SARS-CoV-2 IgM and
 319 IgG in plasma. The most frequent exposure was largely unprotected exposure to aerosol-
 320 generating procedures or patient secretions and close contact without face masks with
 321 other confirmed cases of COVID-19. We measured SARS-CoV-2 antibodies by indirect
 322 chemiluminescence immunoassay (Viracell, Granada, Spain).

323 Cryopreserved plasma was processed for virus inactivation by adding 1500 µL of cold
 324 methanol:ethanol (MeOH:EtOH) in a 1:1 (v/v) proportion to 500 µL of plasma. Then, samples
 325 were vortex-mixed for 1 min, incubated on ice for 5 min and centrifuged at 16,000 x g for 20
 326 min at 4 °C to precipitate and remove proteins. The clean upper layer or supernatant, which
 327 contained the metabolites of interest, was transferred to Eppendorf tubes and stored at -80
 328 °C until analysis.

329 **Sample treatment**

330 Two hundred microliters of frozen supernatant was thawed on ice and evaporated to
 331 dryness using a SpeedVac Concentrator System (Thermo Fisher Scientific, Waltham, MA).
 332 Then, it was resuspended in 100 µL of 0.2 mM methionine sulfone (MetS) in 0.1 M formic
 333 acid. Samples were vortex-mixed for 1 min, transferred to a Millipore filter (30 kDa protein

cutoff) and centrifuged for 40 min at 2000 xg at 4 °C. Finally, the ultrafiltrate was transferred to a CE-MS vial for analysis. Quality control samples (QC) were prepared by pooling equal volumes of plasma supernatant from each sample and were treated as previously described. Finally, blank solutions were also prepared with MeOH:EtOH (1:1, v/v).

Nontargeted metabolomics by CE-MS

The plasma metabolome was analyzed by using a 7100 capillary electrophoresis (CE) system coupled to a 6230 time-of-flight mass spectrometer (TOF-MS) from Agilent Technologies equipped with an electrospray ionization (ESI) source. The analysis was performed using a previously developed method (43) with the analytical conditions described in detail in the Supporting Information. The prepared QCs were analyzed at the beginning of the run to condition the CE system and then every seven randomized samples to reduce any time-related effect. The QCs were used not only to assess the reproducibility, stability and performance of the system but also to correct any signal deviation within the analytical sequence. A pair of blanks were injected at the beginning and end of the run to remove metabolites coming from the extraction solvent.

Data processing

CE-MS raw data were checked using MassHunter Qualitative software (version 10.0) to determine the data quality, the system mass accuracy and the reproducibility of the QC sample and IS injections. Then, raw data were aligned and processed with MassHunter Profinder software (version 10.0 SP1). Molecular feature extraction (MFE) and batch recursive feature extraction (RFE) algorithms, both included in MassHunter Profinder software, were used to obtain the list of mass-to-charge ratios (m/z) and their corresponding abundances (43). The resulting list was imported in Microsoft Excel, and the data matrix was filtered before statistical analysis by removing metabolites with a

percentage of coefficient of variation (% CV) greater than 30% in the QC samples. All the data processing steps are described in detail in the Supporting Information.

Statistics

Multivariate (MVDA) and univariate (UVDA) statistical analyses were carried out to determine differences among groups. Different comparisons were performed to evaluate COVID-19 disease, disease severity, disease progression, and susceptibility. For this purpose, samples were labeled based on the comparison as infected or noninfected for disease diagnosis; susceptible or nonsusceptible for disease susceptibility; mild, moderate or severe at day 0 (d0) for disease severity; or day 0 and day 8 for disease progression. Then, the filtered matrix obtained in the previous step was processed by SIMCA-P version 15.0.2 (Umetrics, Umea, Sweden), MATLAB software (The MathWorks, Maticks, MA, USA), MetaboAnalyst 5.0 and SPSS version 24 (IBM SPSS Statistics) for different purposes. When needed, the intensity drop was corrected with the QC correction function included in the toolbox freely available online at <https://github.com/Biospec/cluster-toolbox-v2.0>. Statistical analysis is described in more detail in the Supporting Information. Briefly, unsupervised PCA was performed to visualize tendencies, determine the presence of outliers, and assess data quality by the explained variance (R^2) and the predicted variance (Q^2), considering as an appropriate value a difference between them of lower than 0.3 (15). Then, the supervised methods PLS-DA and OPLS-DA were performed followed by model validation. In those validated OPLS-DA models, variable selection was performed by using a variable influence on projection (VIP) and absolute value of $p(\text{corr})$ greater than 1.0 and 0.5, respectively (14). Afterwards, UVDA was performed simultaneously to assess the significance of each metabolite separately. In short, nonparametric tests were applied for the comparisons previously mentioned as follows: a) the Kruskal-Wallis test for disease severity (mild, moderate, and severe patients at d0) followed by a multiple comparison test; b) the Wilcoxon signed-rank test for disease progression; and c) the Mann-Whitney U test

for COVID-19 disease and susceptibility. In all cases, the p -value had to be less than 0.05, and the false discovery rate at a level of $\alpha = 0.05$ was controlled by the Benjamini-Hochberg correction test. Finally, ASCA was applied to study the influence associated with sex and age (44). When the ASCA model was not validated by permutation testing, analysis of covariance (ANCOVA) was carried out to eliminate the variability associated with age, sex or both (45).

Metabolite identification

The selected features in the statistical step by UVDA or MVDA were tentatively identified based on the m/z of the metabolites and the relative mobility time (RMT) ($RT_{\text{metabolite}}/RT_{\text{MetS}}$) by using the CEU Mass Mediator (<http://ceumass.eps.uspceu.es/mediator>) (46), which is an ‘in-house’ useful tool for identification. This tool joins several databases, which are available online, such as METLIN (47), LIPIDMAPS (48), and KEGG (49), making the identification task faster and easier. Features assigned to metabolites have to fulfill an appropriate mass accuracy (maximum error mass of 15 ppm), as well as a comparable isotopic pattern distribution. Once metabolites were identified, confirmation was performed by injecting commercial standards, samples, and samples spiked with standards. Finally, for fragmentation pattern recognition, the QC sample was analyzed under the same analytical conditions as used in the previous analysis but applying different voltages in the MS fragmentor (150, 175 and 200 V) (50). It is important to point out that any drug associated with COVID-19 treatments that was identified among the significant metabolites was excluded from both MVDA and UVDA statistical analysis.

Study approval

The study was carried out at the Ramón and Cajal University Hospital in Madrid (Spain) and was approved by the local Research Ethics Committee (ceic.hrc@salud.madrid.org,

408 approval number 095/20). All subject unable to provide informed consent or witnessed oral
409 consent with written consents by a representative were excluded.

410 **Contributors**

411 O.E.A., S.S-V., and C.B study design and conceptualization; S.S-V., D.J., M.S-C., P.V., R.R.,
412 S.H., J.M-S. and S.M. recruited and clinical follow-up; D.J. handling of clinical specimens
413 and data mining; O.E.A., C.B., measurement of plasma metabolites; O.E.A. and S.S-V
414 statistical analysis; O.E.A. and C.B bioinformatic analyses; O.E.A. writing of the first version
415 of the manuscript. All the authors reviewed and approved the manuscript.

416 **Declaration of Interest**

417 Authors declare that no competing interests exist

418 **Acknowledgments**

419 We thank to all patients and healthcare workers who participated in the study.

420 **Fundings**

421 This work was supported by Instituto de Salud Carlos III (AC17/00019, PI18/00154,
422 COV20/00349, ICI20/00058; PI21/00141), CRUE-Supera COVID, cofinanced by the European
423 Development Regional Fund “A way to achieve Europe” (ERDF), Merck, Sharp & Dohme
424 Investigator Studies Program (code MISP# IIS 60257), and Fondo Supera COVID-19 (2020-
425 001).

426 **Data availability**

Participant's metadata and abundances of the key metabolites are displayed in the supplemental table as a supplementary data file.

References

1. Wu D, Shu T, Yang X, Song J-X, Zhang M, Yao C, et al. Plasma metabolomic and lipidomic alterations associated with COVID-19. *National Science Review* [Internet]. 2020;7(7):1157–68. Available from: <https://doi.org/10.1093/nsr/nwaa086>
2. Roberts I, Muelas MW, Taylor JM, Davison AS, Xu Y, Grixti JM, et al. Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome. *medRxiv* [Internet]. 2020;2020.12.09.20246389. Available from: <http://medrxiv.org/content/early/2020/12/11/2020.12.09.20246389.abstract>
3. Thomas T, Stefanoni D, Reisz JA, Nemkov T, Bertolone L, Francis RO, et al. COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status. *JCI insight*. 2020 Jul 23;5(14):e140327. doi: 10.1172/jci.insight.140327.
4. Overmyer KA, Shishkova E, Miller IJ, Balnis J, Bernstein MN, Peters-Clarke TM, et al. Large-Scale Multi-omic Analysis of COVID-19 Severity. *Cell systems*. 2020;
5. Kimhofer T, Lodge S, Whiley L, Gray N, Loo RL, Lawler NG, et al. Integrative Modeling of Quantitative Plasma Lipoprotein, Metabolic, and Amino Acid Data Reveals a Multiorgan Pathological Signature of SARS-CoV-2 Infection. *Journal of proteome research*. 2020 Nov 6;19(11):4442–54.
6. Delafiori J, Navarro LC, Siciliano RF, de Melo GC, Busanello ENB, Nicolau JC, et al. Covid-19 Automated Diagnosis and Risk Assessment through Metabolomics and Machine Learning. *Analytical Chemistry*. 2021 Feb 2;93(4):2471–9.
7. Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic Characterization of COVID-19 Patient Sera. *Cell*. 2020;182(1):59-72.e15.
8. Doğan HO, Şenol O, Bolat S, Yıldız ŞN, Büyüktuna SA, Sariismailoğlu R, et al. Understanding the pathophysiological changes via untargeted metabolomics in COVID-19 patients. *Journal of medical virology*. 2020 Dec 10;
9. Song JW, Lam SM, Fan X, Cao WJ, Wang SY, Tian H, et al. Omics-Driven Systems Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. *Cell metabolism*. 2020 Aug 4;32(2):188-202.e5.
10. Mamani-Huanca M, Gradillas A, Gil de la Fuente A, López-González Á, Barbas C. Unveiling the Fragmentation Mechanisms of Modified Amino Acids as the Key for Their Targeted Identification. *Analytical Chemistry*. 2020 Apr 7;92(7):4848–57.

- 460 11. Khan AP, Rajendiran TM, Bushra A, Asangani IA, Athanikar JN, Yocum AK, et al. The Role of
461 Sarcosine Metabolism in Prostate Cancer Progression. *Neoplasia* [Internet]. 2013;15(5):491-
462 IN13. Available from: <https://www.sciencedirect.com/science/article/pii/S1476558613800358>
- 463 12. Wilson Tang WH, Tong W, Shrestha K, Wang Z, Levison BS, Delfraino B, et al. Differential effects
464 of arginine methylation on diastolic dysfunction and disease progression in patients with
465 chronic systolic heart failure. *European heart journal* [Internet]. 2008;29(20):2506–13.
466 Available from: <https://doi.org/10.1093/eurheartj/ehn360>
- 467 13. Showalter MR, Cajka T, Fiehn O. Epimetabolites: discovering metabolism beyond building and
468 burning. *Current opinion in chemical biology* [Internet]. 2017;36:70–6. Available from:
469 <https://www.sciencedirect.com/science/article/pii/S1367593117300121>
- 470 14. Wheelock ÅM, Wheelock CE. Trials and tribulations of 'omics data analysis: assessing quality of
471 SIMCA-based multivariate models using examples from pulmonary medicine. *Molecular*
472 *bioSystems*. 2013 Nov;9(11):2589–96.
- 473 15. Godzien J, Ciborowski M, Angulo S, Barbas C. From numbers to a biological sense: How the
474 strategy chosen for metabolomics data treatment may affect final results. A practical example
475 based on urine fingerprints obtained by LC-MS. *Electrophoresis*. 2013 Oct;34(19):2812–26.
- 476 16. <https://www.uniprot.org/>.
- 477 17. Li S, Ma F, Yokota T, Garcia Jr G, Palermo A, Wang Y, et al. Metabolic reprogramming and
478 epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity. *JCI insight*. 2021 Jan
479 25;6(2):e145027. doi: 10.1172/jci.insight.145027.
- 480 18. Krishnan S, Nordqvist H, Ambikan AT, Gupta S, Sperk M, Svensson-Akusjärvi S, et al. Implications
481 of central carbon metabolism in SARS-CoV-2 replication and disease severity. *bioRxiv* [Internet].
482 2021;2021.02.24.432759. Available from:
483 <http://biorxiv.org/content/early/2021/02/24/2021.02.24.432759.abstract>
- 484 19. Páez-Franco C. J, Torres-Ruiz J, Sosa-Hernández A. V, Cervantes-Díaz R, Romero-Ramírez S,
485 Pérez-Fragoso A, et al. Metabolomics analysis reveals a modified amino acid metabolism that
486 correlates with altered oxygen homeostasis in COVID-19 patients. *Scientific reports* [Internet].
487 2021;11(1):6350. Available from: <https://pubmed.ncbi.nlm.nih.gov/33737694>
488 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973513/>
- 489 20. Tanianskii DA, Jarzebska N, Birkenfeld AL, O'Sullivan F. J, Rodionov RN. Beta-Aminoisobutyric
490 Acid as a Novel Regulator of Carbohydrate and Lipid Metabolism. *Nutrients* [Internet].
491 2019;11(3):524. Available from: <https://pubmed.ncbi.nlm.nih.gov/30823446>
492 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6470580/>
- 493 21. Stautemas J, van Kuilenburg ABP, Stroomer L, Vaz F, Blancquaert L, Lefever FBD, et al. Acute
494 Aerobic Exercise Leads to Increased Plasma Levels of R- and S-β-Aminoisobutyric Acid in
495 Humans. *Frontiers in physiology*. 2019 Sep 25;10:1240.

- 496 22. Böger RH. Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase,
497 explains the “L-arginine paradox” and acts as a novel cardiovascular risk factor. The Journal of
498 nutrition. 2004 Oct;134(10 Suppl):2842S-2847S; discussion 2853S.
- 499 23. Tsikas D, Bollenbach A, Hanff E, Kayacelebi AA. Asymmetric dimethylarginine (ADMA),
500 symmetric dimethylarginine (SDMA) and homoarginine (hArg): the ADMA, SDMA and hArg
501 paradoxes. Cardiovascular diabetology. 2018 Jan 4;17(1):1–x.
- 502 24. Wink DA, Hines HB, Cheng RY, Switzer CH, Flores-Santana W, Vitek MP, et al. Nitric oxide and
503 redox mechanisms in the immune response. Journal of leukocyte biology. 2011 Jun;89(6):873–
504 91.
- 505 25. Ibiza S, Serrador JM. The role of nitric oxide in the regulation of adaptive immune responses.
506 Inmunología [Internet]. 2008;27(3):103–17. Available from:
507 <https://www.sciencedirect.com/science/article/pii/S0213962608700581>
- 508 26. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary
509 Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. The New England journal
510 of medicine. 2020 Jul 9;383(2):120–8.
- 511 27. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T, et al. Differential metabolomics
512 reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione
513 consumption. The Journal of biological chemistry. 2006 Jun 16;281(24):16768–76.
- 514 28. Irino Y, Toh R, Nagao M, Mori T, Honjo T, Shinohara M, et al. 2-Aminobutyric acid modulates
515 glutathione homeostasis in the myocardium. Scientific Reports [Internet]. 2016;6(1):36749.
516 Available from: <https://doi.org/10.1038/srep36749>
- 517 29. Kotecha T, Knight DS, Razvi Y, Kumar K, Vimalasvaran K, Thornton G, et al. Patterns of
518 myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular
519 magnetic resonance. European heart journal [Internet]. 2021;42(19):1866–78. Available from:
520 <https://doi.org/10.1093/eurheartj/ehab075>
- 521 30. Lehmann F, Tiralongo E, Tiralongo J. Sialic acid-specific lectins: occurrence, specificity and
522 function. Cellular and molecular life sciences : CMLS. 2006 Jun;63(12):1331–54.
- 523 31. Li MN, Qian SH, Yao ZY, Ming SP, Shi XJ, Kang PF, et al. Correlation of serum N-Acetylneuraminic
524 acid with the risk and prognosis of acute coronary syndrome: a prospective cohort study. BMC
525 cardiovascular disorders. 2020 Sep 10;20(1):404–z.
- 526 32. Hu W, Xie J, Zhu T, Meng G, Wang M, Zhou Z, et al. Serum N-Acetylneuraminic Acid Is Associated
527 with Atrial Fibrillation and Left Atrial Enlargement. Cardiology research and practice. 2020 Apr
528 13;2020:1358098.
- 529 33. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med [Internet]. 2020;383(23):2255–73.
530 Available from: <https://doi.org/10.1056/NEJMra2026131>
- 531 34. Favre D, Mold J, Hunt PW, Kanwar B, Loke P, Seu L, et al. Tryptophan catabolism by indoleamine
532 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Science

translational medicine [Internet]. 2010;2(32):32ra36. Available from:
<https://pubmed.ncbi.nlm.nih.gov/20484731>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3034445/>

35. Byakwaga H, Boum 2nd Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD, et al. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. *The Journal of infectious diseases*. 2014 Aug 1;210(3):383–91.

36. Blasco H, Bessy C, Plantier L, Lefevre A, Piver E, Bernard L, et al. The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism. *Scientific reports*. 2020 Oct 8;10(1):16824–5.

37. Meyer KC, Arend RA, Kalayoglu M v, Rosenthal NS, Byrne GI, Brown RR. Tryptophan metabolism in chronic inflammatory lung disease. *The Journal of laboratory and clinical medicine*. 1995 Dec;126(6):530–40.

38. Samelson-Jones BJ, Yeh SR. Interactions between nitric oxide and indoleamine 2,3-dioxygenase. *Biochemistry*. 2006 Jul 18;45(28):8527–38.

39. Badawy AA. Kynurenine Pathway of Tryptophan Metabolism: Regulatory and Functional Aspects. *International journal of tryptophan research: IJTR*. 2017 Mar 15;10:1178646917691938.

40. Huckle C, MacKenzie CR, Adjogble KD, Takikawa O, Däubener W. Nitric oxide-mediated regulation of gamma interferon-induced bacteriostasis: inhibition and degradation of human indoleamine 2,3-dioxygenase. *Infection and immunity*. 2004 May;72(5):2723–30.

41. Fanelli V, Vlachou A, Ghannadian S, Simonetti U, Slutsky AS, Zhang H. Acute respiratory distress syndrome: new definition, current and future therapeutic options. *Journal of thoracic disease* [Internet]. 2013;5(3):326–34. Available from: <https://pubmed.ncbi.nlm.nih.gov/23825769>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698298/>

42. Prevention C for disease C and. Interim Operational Considerations for Public Health Management of Healthcare Workers Exposed to or with Suspected or Confirmed COVID-19: non-U.S. Healthcare Settings.

43. Naz S, Garcia A, Rusak M, Barbas C. Method development and validation for rat serum fingerprinting with CE-MS: application to ventilator-induced-lung-injury study. *Analytical and bioanalytical chemistry* [Internet]. 2013;405(14):4849–58. Available from: <http://europepmc.org/abstract/MED/23535741> <https://doi.org/10.1007/s00216-013-6882-5>

44. Smilde AK, Jansen JJ, Hoefsloot HC, Lamers RJ, van der Greef J, Timmerman ME. ANOVA-simultaneous component analysis (ASCA): a new tool for analyzing designed metabolomics data. *Bioinformatics (Oxford, England)*. 2005 Jul 1;21(13):3043–8.

45. Khammar A, Yarahmadi M, Madadzadeh F. What Is Analysis of Covariance (ANCOVA) and How to Correctly Report Its Results in Medical Research? *Iranian journal of public health* [Internet].

2020;49(5):1016–7. Available from: <https://pubmed.ncbi.nlm.nih.gov/32953697>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7475615/>

46. Mamani-Huanca M, de la Fuente AG, Otero A, Gradillas A, Godzien J, Barbas C, et al. Enhancing confidence of metabolite annotation in Capillary Electrophoresis-Mass Spectrometry untargeted metabolomics with relative migration time and in-source fragmentation. *Journal of chromatographyA*. 2021 Jan 4;1635:461758.

47. Smith CA, O'Maille G, Want EJ, Qin C, Trauger SA, Brandon TR, et al. METLIN: a metabolite mass spectral database. *Therapeutic drug monitoring*. 2005 Dec;27(6):747–51.

48. Fahy E, Subramaniam S, Murphy RC, Nishijima M, Raetz CRH, Shimizu T, et al. Update of the LIPID MAPS comprehensive classification system for lipids. *Journal of lipid research* [Internet]. 2009;50 Suppl:S9–14. Available from: <https://pubmed.ncbi.nlm.nih.gov/19098281>
<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674711/>

49. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research*. 2000 Jan 1;28(1):27–30.

50. Godzien J, Armitage EG, Angulo S, Martinez-Alcazar MP, Alonso-Herranz V, Otero A, et al. In-source fragmentation and correlation analysis as tools for metabolite identification exemplified with CE-TOF untargeted metabolomics. *Electrophoresis*. 2015 Sep;36(18):2188–95.

Figure Legends

Fig 1. Untargeted metabolomic profiles of COVID19+ vs COVID19- and susceptible vs. non-susceptible participants using supervised OPLS-DA models for CE-MS data. (A) Plot A represents the comparison of COVID19+ and COVID19- individuals ($R^2 = 0.878$, $Q^2 = 0.813$), and CV-ANOVA (p -value = 2.10×10^{-19}). (B) Plot B represents the comparison of susceptible and non-susceptible participants with $R^2 = 0.902$, $Q^2 = 0.817$, and CV-ANOVA p -value = 4.20×10^{-17} . Models were validated by permutation testing and CV-ANOVA (14,15). Hydroxychloroquine, initially found to be significant, was removed from all statistical analysis as it was empirically used to treat COVID19 at the time of sample collection.

Fig 2. Untargeted metabolomic profiles of participants with COVID19 according to clinical severity using supervised OPLS-DA models for CE-MS data. (A) Mild vs. moderate disease; $R^2 = 0.713$, $Q^2 = 0.009$, and CV-ANOVA p -value = 0.997. (B) Mild vs. severe disease; $R^2 = 0.929$,

600 $Q^2 = 0.675$, and CV-ANOVA p -value = 0.010. (C) Moderate vs. severe disease; $R^2 = 0.897$, Q^2
 601 = 0.636, and CV-ANOVA p -value = 0.027.

602 **Fig 3. Untargeted metabolomic profiles at baseline and day 8 of participants with mild and**
 603 **moderate COVID19 supervised OPLS-DA models for CE-MS data.** (A) Plot A represents the
 604 differences in mild cases ($R^2 = 0.816$, $Q^2 = 0.596$; CV-ANOVA p -value = 0.062). (B) Plot B
 605 represents the differences in moderate cases ($R^2 = 0.961$, $Q^2 = 0.716$; CV-ANOVA p -value =
 606 0.014).

607 **Fig 4. Heatmap with group average of statistically significant metabolites detected in human**
 608 **plasma samples by CE-MS modified by virus SARS-CoV-2 virus infection.** In green, metabolites
 609 involved in TCA cycle. In purple, those involved in kynurenine pathway. In blue those
 610 compounds of the nitric oxide or are related with NO regulation.

611 **Fig 5. A model of the metabolic pathways implicated in COVID19 pathogenesis.** Impairment
 612 of blood oxygenation following SARS-CoV-2 damage results in 1) inefficient mitochondrial
 613 metabolism in the liver, resulting in dysregulation of the urea cycle citrulline decreases,
 614 phenylalanine increases; 2) dysregulation of energy metabolism and amino acid
 615 metabolism, resulting in decreased L-serine, L-alanine, and L-serine; 3) activation of
 616 oxidative stress response, resulting in BAIBA accumulation, L-ADMA upregulation, and
 617 induction of the kynurenine pathway, which impairs mucosal immunity, allowing bacterial
 618 superinfections. Figure generated using biorender.com.

619

620